Abstract
From January 1983 to October 1990, 41 patients with generalised myasthenia gravis were randomly given either prednisone or azathioprine. The main goal was to record the time to the occurrence of the first episode of deterioration. During a mean follow-up of 30 months, 21 patients showed deterioration, 12 in the prednisone group and nine in the azathioprine group (p = 0.40). No difference was observed between the two groups in muscular score and functional grade, assessed at the end of each treatment year, or in tolerance. Treatment failure occurred in 17 patients, 12 in the prednisone group and five in the azathioprine group (p = 0.02); even after adjustment for imbalances in prognostic features, the failure rate remained 2.8 times higher in the prednisone group than in the azathioprine group (p = 0.5). In the patients in whom treatment failed, symptoms were initially more severe than in the others, but the combination of prednisone and azathioprine resulted in clinical improvement, consisting of remission or only minor deficits in half of the patients after two years of treatment. These findings indicate that azathioprine increases treatment response compared with prednisone, although no difference in the duration of improvement was demonstrated. Nevertheless, it appears that the most severe forms of the disease, often resistant to prednisone or azathioprine alone, could benefit from the combination of both drugs.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Felson D. T., Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med. 1984 Dec 13;311(24):1528–1533. doi: 10.1056/NEJM198412133112402. [DOI] [PubMed] [Google Scholar]
- Fonseca V., Havard C. W. Long term treatment of myasthenia gravis with azathioprine. Postgrad Med J. 1990 Feb;66(772):102–105. doi: 10.1136/pgmj.66.772.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- George S. L., Desu M. M. Planning the size and duration of a clinical trial studying the time to some critical event. J Chronic Dis. 1974 Feb;27(1):15–24. doi: 10.1016/0021-9681(74)90004-6. [DOI] [PubMed] [Google Scholar]
- Grob D., Arsura E. L., Brunner N. G., Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci. 1987;505:472–499. doi: 10.1111/j.1749-6632.1987.tb51317.x. [DOI] [PubMed] [Google Scholar]
- Johns T. R. Long-term corticosteroid treatment of myasthenia gravis. Ann N Y Acad Sci. 1987;505:568–583. doi: 10.1111/j.1749-6632.1987.tb51325.x. [DOI] [PubMed] [Google Scholar]
- Mertens H. G., Hertel G., Reuther P., Ricker K. Effect of immunosuppressive drugs (azathioprine). Ann N Y Acad Sci. 1981;377:691–699. doi: 10.1111/j.1749-6632.1981.tb33767.x. [DOI] [PubMed] [Google Scholar]
- Pascuzzi R. M., Coslett H. B., Johns T. R. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984 Mar;15(3):291–298. doi: 10.1002/ana.410150316. [DOI] [PubMed] [Google Scholar]
- Rowland L. P. Controversies about the treatment of myasthenia gravis. J Neurol Neurosurg Psychiatry. 1980 Jul;43(7):644–659. doi: 10.1136/jnnp.43.7.644. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sghirlanzoni A., Peluchetti D., Mantegazza R., Fiacchino F., Cornelio F. Myasthenia gravis: prolonged treatment with steroids. Neurology. 1984 Feb;34(2):170–174. doi: 10.1212/wnl.34.2.170. [DOI] [PubMed] [Google Scholar]
- Witte A. S., Cornblath D. R., Parry G. J., Lisak R. P., Schatz N. J. Azathioprine in the treatment of myasthenia gravis. Ann Neurol. 1984 Jun;15(6):602–605. doi: 10.1002/ana.410150615. [DOI] [PubMed] [Google Scholar]